skip to Main Content

Empower your members to take control of their heart health

The increasing number of arrhythmia patients places a heavy burden on healthcare systems

80%

of cardiovascular disease can be prevented by investing in early detection and treatment1

1 in 3

develops atrial fibrillation (AF) after the age of 552

5X

increased risk for heart failure and stroke due to arrhythmias3

256

million working days lost every year linked to heart conditions in the EU4

How adding FibriCheck can improve your offering

How adding FibriCheck can improve your offering

FibriCheck, your heart health partner

FibriCheck is a clinically validated, medical-grade app that facilitates the remote detection and monitoring of cardiac arrhythmias, including atrial fibrillation (AF), using only a smartphone. It allows users to measure heart rate and heart rhythm, and also enables users to follow up on their blood pressure, weight and symptoms.

By offering FibriCheck, you provide peace of mind to individuals concerned about their heart health by delivering real-time insights into their heart rate and rhythm, leading to fewer doctor visits. As 40% of people suffering from AF doesn’t experience any symptoms6. FibriCheck can also be deployed as a powerful detection tool for this population, guiding people who need it to the correct next steps, while reducing the amount of unnecessary doctor appointments at the same time. With early diagnosis and treatment, the risk of costly complications such as stroke decrease significantly.

FibriCheck also offers valuable insights into the overall health of your member base, allowing for better identification of at-risk individuals and more effective prevention strategies. This not only improves outcomes but also enhances member engagement and adds value beyond traditional claim management.

Our heart health offering

Approved as medical device in various countries

Patented technology and +80 peer-reviewed publications

Multi-arrhythmia detection, including AF

Large dataset with database of over 1.000.000 users

Device agnostic: compatibility with over 17.500 smartphone models

Some of our implementations

FibriCheck as part of insurance offering by Sanitas, part of Bupa

Reduced time to diagnosis Added value for members Long term cost savings Sustainable and future proof insurance package

read more

Empowering people to follow up on their heart health with healthcare insurer Helan

Focus on prevention Insights into member heart health Provide tailored education to members Peace of mind offered to members Member…

read more

Healthcare insurer CM empowers members to follow up on their heart health

Focus on prevention Gain deeper insights into at-risk individuals Enhance prevention strategies Reduce costs Offer peace of mind to members

read more

Want to learn more? Book a meeting with our team

Success stories

Get in touch

References
1. EHN, Heart Failure and Cardiovascular Diseases – A European Heart Network Paper (2019)

2. ESC Guidelines (2024)

3. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG et al.. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. Bmj 354 i4482 (2016)

4. Oxford population health, Cardiovascular disease cost the European Union economy €282bn in 2021 (2023)

5. Dr. Betz, K. (2023, April 18). Changes in healthcare utilisation and declarable care products during the implementation of a remote atrial fibrillation management pathway: The TeleCheck-AF project [e-cardiology award session]. EHRA 2023, Barcelona

6. Xiong Q., Proietti M., Senoo K., Y H Lip G. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes (2015)

Back To Top
Search